British Columbia Cancer Agency

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia (2020) Sharma A, Jyotsana N, Gabdoulline R, Heckl D, Kuchenbauer F, Slany R, Ganser A, Heuser M Journal article Renal Cell Carcinoma with "Gonadal Sex-cord Stromal tumor-like" Features: Analysis of 5 Cases of Novel Renal Entity (2020) Wang G, Amin M, Grossmann P, Hayes M, Hartmann A, Agaimy A, Lopez J, Hes O Conference contribution Eleven grand challenges in single-cell data science (2020) Laehnemann D, Koester J, Szczurek E, Mccarthy DJ, Hicks SC, Robinson MD, Vallejos CA, et al. Journal article, Review article Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer (2020) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium (2020) Martins FC, Couturier DL, Paterson A, Karnezis AN, Chow C, Nazeran TM, Odunsi A, et al. Journal article Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press (2020) Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, et al. Journal article, Editorial Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer (2019) Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO, Rieker R, Levins C, et al. Journal article Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk (2019) Yang Y, Wu L, Shu X, Lu Y, Shu XO, Cai Q, Beeghly-Fadiel A, et al. Journal article